SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now

Affiliations

¹ Program Director, Nephrology and Hypertension Fellowship, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Co-investigator, EMPA-KIDNEY study talierj@ccf.org.
² Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Principal Investigator, EMPA-KIDNEY study.
³ Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Co-investigator, EMPA-KIDNEY study.
⁴ Department of Hypertension and Nephrology, Glickman Urological and Kidney Institute, Cleveland Clinic; Clinical Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Principal Investigator, EMPA-KIDNEY study.
⁵ Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.

Free article

Editorial

Jonathan J Taliercio et al. Cleve Clin J Med. 2021.

Free article

. 2021 Jan 1;88(1):59-63.

doi: 10.3949/ccjm.88a.20190.

¹ Program Director, Nephrology and Hypertension Fellowship, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Co-investigator, EMPA-KIDNEY study talierj@ccf.org.
² Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Principal Investigator, EMPA-KIDNEY study.
³ Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Co-investigator, EMPA-KIDNEY study.
⁴ Department of Hypertension and Nephrology, Glickman Urological and Kidney Institute, Cleveland Clinic; Clinical Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Principal Investigator, EMPA-KIDNEY study.
⁵ Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.

No abstract available

Comment on

The role of SGLT-2 inhibitors in managing type 2 diabetes.
Tsushima Y, Lansang MC, Makin V. Tsushima Y, et al. Cleve Clin J Med. 2021 Jan 1;88(1):47-58. doi: 10.3949/ccjm.88a.20088. Cleve Clin J Med. 2021. PMID: 33384315